jiangjingting
Quick facts
Marketed products
- IL-2 pre-treated CD19 cells · Oncology
IL-2 pre-treated CD19-targeted cells enhance immune recognition and elimination of CD19-expressing B-cell malignancies through cytokine-primed cellular immunity. - IL-7/IL-15 pre-treated CD19 cells · Oncology
IL-7/IL-15 pre-treated CD19-targeted CAR-T cells enhance T cell proliferation and persistence to attack CD19-positive B-cell malignancies.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: